This growing resistance to activin may be due to the inherent increased malignancy of ER-negative breast cancer cells compared with that of ER-positive cells, or because activin and estrogen can antagonize each other’s biological activities in human breast cancer cells [104]. Here, ESR1 is linked to breast carcinoma.